Table 1: Kinase Inhibitors Against Cell Cycle Targets

Generic Name Target Source
Seliciclib CDK2; CDK7; CDK9; MCL1 Cyclacel Pharmaceuticals Inc
ON-01910Na CDC2; PDGFRB; PLK1 Onconova Therapeutics Inc
SCH-727965 CDC2; CDK2; CDK9 Schering-Plough Corp
No Name Given AuroraA and AuroraB Astrazeneca
No Name Given CDK2, CDK4, CDK6 and FAK AstraZeneca
VX-680.HCl; MK-0457 Aurora-1,Aurora-2,Aurora-3;Flt-3;JAK2;RET Vertex; Merck
AG-024322 CDC2; CDK2; CDK4 Pfizer Inc
Purvalanol A multi-targeted CDK The Regents of the Univ. Cali.
No Name Given CDK2, CDK4, CDK6 and FAK AstraZeneca
No Name Given PLK-1 GSK/Banyu
No Name Given CDK1, CDK2, CDK3 AstraZeneca
BMI-1026 CDK1 Biomedical Institute (USA)
PD-171851 CDK4 Pfizer Inc
AG-12286 CDK Agouron/Pfizer
PHA-680632 Aurora A, Aurora B, Aurora C and RTK Nerviano, Pfizer
BI2536 PLK-1 Boehringer Ingelheim
H-7 CDK7 University of California
Indenopyrazole/Quinazoline CDK Bristol-Myers Squibb Co
No Name Given PLK-1 Smithkline Beecham
Aurora A Kinase AURKA; PRKG1 GPC
ON-01910Na PLK1, CDK1 Onconova
No Name Given CDKs, FAK Astrazeneca
Berlex CDK4 Bayer AG
No Name Given PLK-1 Smithkline Beecham
No Name Given CDKs FAK Astrazeneca
No Name Given WEE1 ChemExplorer
BI-2536 PLK1 Boehringer Ingelheim Corp
No Name Given Aurora A AstraZeneca
GSK-461364 PLK1; PLK3 GlaxoSmithKline plc
No Name Given PLK-1 Amgen
HMN-214 PLK-1 Nippon Shinyaku Co
No Name Given CDKs & FAK AstraZeneca
R-547 CDC2; CDK2; CDK4 Roche
No Name Given CDKs & FAK Astrazeneca
HMN-214 PLK1 Nippon Shinyaku
PD-332991 CDK4; CDK6 Onyx Pharmaceuticals Inc
PHA-739358 ABL1;AURKA;AURKB;FGFR1;NTRK1;RET Nerviano Medical Sciences
AZD-1152 AURKA; AURKB AstraZeneca plc
CDK inhibitor CDK Johnson & Johnson
Tozasertib Lactate ABL1; AURKA; AURKB; BCR; FLT3; JAK2 Vertex Pharmaceuticals Inc
SNS-032 CDK2; CDK7; CDK9; MCL1 Bristol-Myers Squibb Co
BMS-265246 CDC2; CDK2 Bristol-Myers Squibb Co
MLN-8054 AURKA Takeda Pharmaceutical
Alvocidib CDC2; CDK2; CDK4; CDK9 US Government